Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1280662 | 0.99 | SLC6A2 (0.72) | SLC6A2SLC6A4 | |
| SCHEMBL1286441 | 0.94 | SLC6A2 (0.70) | SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL1279780 | 0.93 | SLC6A2 (0.71) | SLC6A2SLC6A4 | |
| SCHEMBL1280799 | 0.91 | SLC6A2 (0.67) | SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL1281166 | 0.91 | SLC6A2 (0.68) | SLC6A2SLC6A4 | |
| SCHEMBL1697833 | 0.88 | SLC6A2 (0.67) | SLC6A2SLC6A4 | |
| SCHEMBL1281936 | 0.88 | SLC6A2 (0.67) | SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL1280833 | 0.87 | SLC6A2 (0.68) | SLC6A2SLC6A4 | |
| SCHEMBL1281052 | 0.87 | SLC6A2 (0.80) | SLC6A2SLC6A4 | |
| SCHEMBL1281557 | 0.86 | SLC6A2 (0.73) | SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722662-B2 | Heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-13 | — | — | US | disclosed |
| US-8722662-B2 | Heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-13 | — | — | US | disclosed |
| US-8722662-B2 | Heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-13 | — | — | US | disclosed |
| US-20130267494-A1 | 1,4-OXAZEPANE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-10 | — | — | US | disclosed |
| US-20130267494-A1 | 1,4-OXAZEPANE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-10 | — | — | US | disclosed |
| US-20130267494-A1 | 1,4-OXAZEPANE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-10 | — | — | US | disclosed |
| US-20120088748-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-12 | — | — | US | disclosed |
| US-20120088748-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-12 | — | — | US | disclosed |
| US-20120088748-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-12 | — | — | US | disclosed |
| WO-2012046882-A1 | 1,4-OXAZEPANE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267494-A1 | 1,4-OXAZEPANE DERIVATIVES | MAOB, SLC6A4, SLC6A2 | SLC6A2 3/4885SLC6A4 2/4885 |
| US-20120088748-A1 | HETEROCYCLIC COMPOUNDS | SLC6A2, MAOB, MAOA | SLC6A2 1/4885SLC6A4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.